Perirenal hematoma in a patient treated with bevacizumab for metastatic colon cancer: A case report.
The present study reports the case of a patient that developed spontaneous perirenal hematoma during treatment with bevacizumab-containing chemotherapy. A 44-year-old woman with metastatic sigmoid colon cancer, who was being treated with bevacizumab (5 mg/kg, intravenous, 90 min biweekly), was admitted to hospital following 3 cycles of chemotherapy, with a sudden onset of dyspnea and oliguria. An emergency hemodialysis was performed and a large right perirenal hematoma was diagnosed using computed tomography. The patient was immediately instructed to discontinue chemotherapy, including bevacizumab. However, the right perirenal hematoma increased in size and a left perirenal hematoma developed 3 weeks later. The two perirenal hematomas stabilized 7 weeks subsequent to the termination of bevacizumab treatment. Spontaneous perirenal hematoma due to bevacizumab treatment is an extremely rare occurrence. However, physicians should be aware of this potential complication associated with bevacizumab treatment.
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Min Sung
MS
Lee
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Il Sang
IS
Shin
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
DO Hyung
DH
Kwun
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Se Hyung
SH
Kim
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Hyun Jung
HJ
Kim
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Chan Kyu
CK
Kim
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Seong Kyu
SK
Park
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Dae Sik
DS
Hong
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University School of Medicine, Bucheon Hospital, Bucheon, Gyeonggi 420-767, Republic of Korea.
Jina
J
Yun
bevacizumab; colonic neoplasms; hematoma